The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Open accessPublished version of a preprint
Abstract
Functional genomics approaches can overcome limitations-such as the lack of identification of robust targets and poor clinical efficacy-that hamper cancer drug development. Here we performed genome-scale CRISPR-Cas9 screens in 324 human cancer cell lines from 30 cancer types and developed a data-driven framework to prioritize candidates for cancer therapeutics. We integrated cell fitness effects with genomic biomarkers and target tractability for drug development to systematically prioritize new targets in defined tissues and genotypes. We verified one of our most promising dependencies, the Werner syndrome ATP-dependent helicase, as a synthetic lethal target in tumours from multiple cancer types with microsatellite instability. Our analysis provides a resource of cancer dependencies, generates a framework to prioritize cancer drug targets and suggests specific new targets. The principles described in this study can inform the initial stages of drug development by contributing to a new, diverse and more effective portfolio of cancer drug targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the MSI that often leads to cancer simultaneously makes the inhibition of Werner syndrome ATP-dependent helicase (WRN) lethal to the tumor cells62,63”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [62]
In the citing paper
“''Fitness Scores'' that were calculated from large-scale genome-wide CRISPR/Cas9 screens across 31 independent CRC cell lines and represent a quantitative measure of the reduction of cell viability elicited by a gene inactivation via CRISPR/Cas9 (https://score.depmap.sanger.ac.uk) (Behan et al., 2019;van der Meer et al., 2019).”
From Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer (2021) · cites this paper as Behan et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Statistical significance for genomewide studies
Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r29 · Cited by 6,155
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“Most patients however do not benefit from such targeted therapies in part due to limited knowledge of candidate targets(Zehir et al. 2017).”
Defining a Cancer Dependency Map
Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S., Harrington, W. F., Pantel, S., Krill-Burger, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.010 · Cited by 3,276
Cited by
Sorted by citations
Items 901–999 of 999
Genetic dependencies associated with transcription factor activities in human cancer cell lines
Thatikonda, V., Supper, V., Wachter, J., Kaya, O., Kombara, A., Bilgilier, C., Ravichandran, M. C., Lipp, J., Sharma, R., Badertscher, L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114175 · Cited by 3
Identifying actionable synthetically lethal cancer gene pairs using mutual exclusivity
Wooller, S. K., Pearl, L. H., & Pearl, F. M. G. (2024) · FEBS Letters · doi:10.1002/1873-3468.14950 · Cited by 3
Challenges and Outlooks in Precision Medicine: Expectations Versus Reality
Yan, R., & Greenfield, J. P. (2024) · World Neurosurgery · doi:10.1016/j.wneu.2024.06.142 · Cited by 3
Cohen, Z., Petrenko, E., Barisaac, A. S., Abu‐Zhayia, E. R., Yanovich-Ben-Uriel, C., Ayoub, N., & Aran, D. (2025) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqaf052 · Cited by 3
Z-scores outperform similar methods for analyzing CRISPR paralog synthetic lethality screens
Chou, J., Anvar, N. E., Elghaish, R. A., Chen, J., & Hart, T. (2025) · Genome biology · doi:10.1186/s13059-025-03660-0 · Cited by 4
Ashenden, S. K., Deswal, S., Bulusu, K. C., Bartosik, A., & Shameer, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820045-2.00004-0 · Cited by 4
Targeted Therapies in Lung Cancers: Current Landscape and Future Prospects
Feng, X., Ding, W., Ma, J., Liu, B., & Yuan, H. (2021) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892816666210615161501 · Cited by 3
Xin, Y., You, S., Chen, Y., & Qian, K. (2022) · Journal of Oncology · doi:10.1155/2022/4566577 · Cited by 3
Wang, X., Zhang, S., & Liu, Y. (2021) · Cited by 3
Tsujimoto, A., Matsuo, N., Lai, X., Inoue, T., Yoda, H., Lin, J., Shinozaki, Y., Watanabe, T., Koshikawa, N., Takatori, A., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5359 · Cited by 2
AutoGenome V2: New Multimodal Approach Developed for Multi-Omics ResearchPreprint
Xu, C., Liu, D., Zhang, L., Xu, Z., He, W., Wang, D., Zheng, M., & Qiao, N. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.02.021345 · Cited by 3
VRK1 is a Paralog Synthetic Lethal Target in VRK2-methylated GlioblastomaPreprint
Shields, J. A., Meier, S. R., Bandi, M. L., Ferdinez, M. D., Engel, J. L., Mulkearns-Hubert, E. E., Hajdari, N., Mitchell, K., Zhang, W., Zhao, S.-C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.30.474571 · Cited by 3
Functional genomic analysis of adult and pediatric brain tumor isolatesPreprint
Hoellerbauer, P., Biery, M. C., Arora, S., Rao, Y., Girard, E. J., Mitchell, K., Dighe, P. A., Kufeld, M., Kuppers, D. A., Herman, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.05.522885 · Cited by 3
Self-citationA dual sgRNA library design to probe genetic modifiers using genome-wide CRISPRi screensPreprint
Guna, A., Page, K. R., Replogle, J., Esantsi, T. K., Wang, M. L., Weissman, J. S., & Voorhees, R. (2023) · bioRxiv · doi:10.1101/2023.01.22.525086 · Cited by 8
Picco, G., Rao, Y., Saedi, A. A., Walker, S. J., Bhosle, S. G., Lee, Y., Vieira, S. F., García-Casado, M. A., Garcia, G. V., May, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.23.695783 · Cited by 3
Self-citationCRISPR System and Its Applications in Medicine and Stem Cell Engineering
Abdolmaleki, A., Nahumi, A., Seddigh, H. B., Yazdannasab, N., Panahi, A., Ashique, S., & Asadi, A. (2024) · Gene Cell and Tissue · doi:10.5812/gct-150914 · Cited by 2
SKA3 promotes lung adenocarcinoma progression via the EGFR/E2F1/SKA3/integrin β1 signaling loop
Zheng, X., Sun, Z., Wang, S., Liu, Q., Zhu, B., Ren, Z., Fan, D., Zhang, C., Fu, X., Jin, Y., et al. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05242-x · Cited by 2
Interferon‐Inducible ADAR1 p150 Is Essential for the Survival of Oral Squamous Cell Carcinoma
Yee, P. S., Chai, A. W. Y., Yee, S. M., Ooi, S., Tan, Y. H., Garnett, M. J., Ng, S. K., & Cheong, S. C. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23910 · Cited by 3
Self-citationCancer Dependency Map: Past and Present
Arafeh, R., Shibue, T., Vázquez, F., & Hahn, W. C. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062722-024239 · Cited by 3
Wang, F., Chen, Y., Huang, R., Lu, D., Zhang, J., Yang, Y., Dang, H., Liu, M., Chen, Z., Sun, X., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04034-y · Cited by 2
Drug Repurposing to Inhibit Oncostatin M in Crohn’s Disease
Bahramimehr, F., Guthart, A., Kurz, S., Hai, Y., Dawood, M., Yücer, R., Shahhamzehei, N., Weiskirchen, R., Roth, W., Stremmel, W., et al. (2025) · Molecules · doi:10.3390/molecules30091897 · Cited by 2
Lian, X., Kuang, X., Zhang, D., Xu, Q., Ye, A., Wang, C., Cui, H., Guo, H., Zhang, J., Liu, Y., et al. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf266 · Cited by 2
Farina-Morillas, M., Ollé-Monràs, L., Maas, S. C. E., de Rojas-P, I., Segura, M. F., & Seoane, J. A. (2025) · Epigenomics · doi:10.1080/17501911.2025.2548756 · Cited by 2
Soetomo, S. A., Sharp, M. F., & Crismani, W. (2025) · PLoS ONE · doi:10.1371/journal.pone.0332860 · Cited by 3
Direct Protein Degradation: Emerging Tools to Probe Biological Complexity in Mammalian Systems
Rajalekshmi, S., & Sathyan, K. M. (2025) · BioEssays · doi:10.1002/bies.70075 · Cited by 2
Emerging role of transfer RNA-derived small RNAs (tsRNAs) in hepatocellular carcinoma
Abdelhamid, A. M., Abaza, T., Kotb, W. T., Mohamed, A. H., Gad, M. Z., Metwally, A. M., Coulouarn, C., & Youness, R. A. (2025) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2025.2600544 · Cited by 2
Watterson, A., Picco, G., Veninga, V., Samarakoon, Y., Cattaneo, C. M., Vieira, S. F., Karakoç, E., Bhosle, S. G., Battaglia, T., Consonni, S., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102565 · Cited by 2
Self-citationWang, H., Shen, T., Yang, S., Zhou, X., Cao, P., Yu, H., He, K., Fu, M., Yu, H., Liu, X., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218446 · Cited by 2
Context-dependent synthetic lethality — an emerging precision therapeutic approach
Chang, L., Shaw, K. L., Vázquez, F., & Sellers, W. R. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00929-9 · Cited by 7
Synthetic lethality in cancer: mechanism exploration and therapeutic applications
Zhao, P., Wang, P., Xu, T., Chen, L., Jia, Q., & Li, M. H. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02932-x · Cited by 2
Lu, X., Qin, J., Dong, S., Yuan, Y., Zhang, Z., Zhang, B., Chen, X., Gan, X., Liang, H., & Liu, F. (2026) · Biomarker Research · doi:10.1186/s40364-026-00937-9 · Cited by 3
Inflammatory cytokines induce new cancer dependencies
Cheruiyot, C. K., Kim, S. Y., Dubrot, J., Lane-Reticker, S. K., Miranda, A., Kammula, A. V., Perera, J., Du, P. P., Chuong, C. L., Fetterman, R. A., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02614-x · Cited by 2
Organoid technology in cancer research
Zhang, J., & He, J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00505-5 · Cited by 3
The role of ferroptosis in the pathogenesis and treatment of breast cancer
Zhang, M., Han, Q., Zhao, X., Liu, W., Lu, M., & Li, X. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08594-0 · Cited by 2
Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial
Yap, T. A., Fontana, E., Cook, N., Fakih, M., Bechter, O. E., Tsang, E. S., Calvo, E., Rohrberg, K. S., Ros, J., Matos, I. G., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04657-3 · Cited by 2
Gene Editing in der Krebsforschung: technische, ethische und rechtliche Aspekte
Schmietow, B., Eberbach, W., & Kaulich, M. (2019) · Der Onkologe · doi:10.1007/s00761-019-0599-9 · Cited by 2
Li, S. C. (2019) · Online Journal of Complementary & Alternative Medicine · doi:10.33552/ojcam.2019.01.000514 · Cited by 2
Diffusion kernel-based predictive modeling of KRAS dependency in KRAS wild type cancer cell lines
Ulmer, B., Odenthal, M., Buettner, R., Roth, W., & Kloth, M. T. (2022) · npj Systems Biology and Applications · doi:10.1038/s41540-021-00211-8 · Cited by 2
Deswal, S., Bulusu, K. C., Agapow, P., & Khan, F. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820045-2.00009-x · Cited by 2
Batzilla, A., Lu, J., Kivioja, J. L., Putzker, K., Lewis, J., Zenz, T., & Huber, W. K. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010438 · Cited by 2
Zhao, Y., Yu, L., Wu, X., Li, H., Coombes, K. R., Au, K. F., Cheng, L., & Li, L. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac668 · Cited by 2
Vural-Özdeniz, M., Çalışır, K., Acar, R., Yavuz, A., Ozgur, M. M., Dalgıç, E., & Konu, Ö. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbad536 · Cited by 2
Chai, A. W. Y., Tan, Y. H., Ooi, S., Yee, P. S., Yee, S. M., Lightfoot, H. W., Barthorpe, S., Garnett, M. J., & Cheong, S. C. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0136 · Cited by 2
Self-citationDing, Y., Denomy, C., Freywald, A., Pan, Y. F., Vizeacoumar, F. J., Vizeacoumar, F. S., & Wu, F. (2024) · Cells · doi:10.3390/cells13191653 · Cited by 2
The prominent pervasive oncogenic role and tissue specific permissiveness of RAS gene mutations
Yi, M., Soppet, D. R., McCormick, F. P., & Nissley, D. V. (2024) · Scientific Reports · doi:10.1038/s41598-024-76591-8 · Cited by 2
CRISPR/Cas9 Technology Providing the Therapeutic Landscape of Metastatic Prostate Cancer
Park, J., & Kim, J. (2024) · Pharmaceuticals · doi:10.3390/ph17121589 · Cited by 2
KLF14 inhibits tumor progression via FOSL1 in glioma
Wang, X., Qu, X., Liu, X., Wang, K., Yang, Y., Zhang, Y., Wang, Z., Fan, G., Li, Y., Zeng, Y., et al. (2024) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2024.101885 · Cited by 3
PRODE recovers essential and context-essential genes through neighborhood-informed scores
Cantore, T., Gasperini, P., Bevilacqua, R., Ciani, Y., Sinha, S., Ruppin, E., & Demichelis, F. (2025) · Genome biology · doi:10.1186/s13059-025-03501-0 · Cited by 2
TARGET-SL: precision essential gene prediction using driver prioritisation and synthetic lethality
Gillman, R., Field, M. A., Schmitz, U., & Hebbard, L. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf255 · Cited by 2
Yu, M., Yang, D., Zhu, D., Wang, Y., Cao, M., Zhu, J., Zhu, W., Wang, G., & Aa, J. (2025) · The Journal of Pathology · doi:10.1002/path.6442 · Cited by 2
WD40 Protein NLE1 as a Novel Diagnostic Biomarker Promoting Hepatocellular Carcinoma Proliferation
Zhang, R.-T., Liu, D.-H., Feng, X.-X., Yang, Z.-Y., & Zhang, K.-G. (2025) · Clinical Medicine Insights: Oncology · doi:10.1177/11795549251348902 · Cited by 2
Inducible CRISPR–Cas9 screening platform to interrogate non-proliferative cellular states
Raffi, G. C., Kuiken, H. J., Lieftink, C., Bernards, R., Beijersbergen, R. L., & Wang, L. (2025) · Nature Protocols · doi:10.1038/s41596-025-01251-8 · Cited by 5
CRISPR-Cas genome editing tool: a narrow lane of cancer therapeutics with potential blockades
Bhatkar, D., Sarode, S. C., Sarode, G. S., Patil, S., & Sharma, N. K. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.02.33 · Cited by 1
Computational Drug Target Tractability Analysis
Leach, A. R., & Radoux, C. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11531-4 · Cited by 2
Precision in Cancer Pharmacogenomics
Kyrochristos, I. D., Baltagiannis, E. G., Mitsis, M. C., & Roukos, D. H. (2020) · Pharmacogenomics · doi:10.2217/pgs-2020-0011 · Cited by 2
Cell plasticity and genomic instability in cancer evolution
Xu, Y. K., Li, H., Yang, F., Yang, D., & Zhou, B. S. (2020) · Genome Instability & Disease · doi:10.1007/s42764-020-00023-w · Cited by 2
Smallerp-values in genomics studies using distilled auxiliary information
Bryan, J., & Hoff, P. D. (2020) · Biostatistics · doi:10.1093/biostatistics/kxaa053 · Cited by 2
Gene Signature-Based Drug Repositioning
Jia, Z., Song, X., Shi, J., Wang, W., & He, K. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.101377 · Cited by 2
MUT-7 Provides Molecular Insight into the Werner Syndrome Exonuclease
Hsu, T.-Y., Hsu, L.-N., Chen, S.-Y., & Juang, B.-T. (2021) · Cells · doi:10.3390/cells10123457 · Cited by 2
How has CRISPR Transformed Therapeutic Drug Discovery?
Parker, J. (2023) · BioTechniques · doi:10.2144/btn-2023-0020 · Cited by 2
Theory for High-Throughput Genetic Interaction Screening
McCarthy, M. E., Dodd, W. B., Lu, X., Pritko, D. J., Patel, N. D., Haskell, C. V., Sanabria, H., Blenner, M., & Birtwistle, M. R. (2023) · ACS Synthetic Biology · doi:10.1021/acssynbio.2c00627 · Cited by 2
Tian, P., Zheng, J., Qiao, K., Fan, Y., Xu, Y., Wu, T., Chen, S., Zhang, Y., Zhang, B., Ambrogio, C., et al. (2024) · Advanced Science · doi:10.1002/advs.202412419 · Cited by 2
Kim, I., Lee, H., Lee, K., Han, S. K., Kim, D., & Kim, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-48273-3 · Cited by 2
Computational prediction of CRISPR-impaired non-coding regulatory regions
Baumgarten, N., Schmidt, F., Wegner, M., Hebel, M., Kaulich, M., & Schulz, M. H. (2021) · Biological Chemistry · doi:10.1515/hsz-2020-0392 · Cited by 2
A Resource to Infer Molecular Paths Linking Cancer Mutations to Perturbation of Cell Metabolism
Iannuccelli, M., Surdo, P. L., Licata, L., Castagnoli, L., Cesareni, G., & Perfetto, L. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.893256 · Cited by 2
Lineage specific core-regulatory circuits determine gene essentiality in cancer cellsPreprint
Rauscher, B., Henkel, L., Heigwer, F., & Boutros, M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/609552 · Cited by 2
Personalized Cancer Therapy Prioritization Based on Driver Alteration Co-occurrence PatternsPreprint
Mateo, L., Duran‐Frigola, M., Gris‐Oliver, A., Palafox, M., Scaltriti, M., Razavi, P., Chandarlapaty, S., Arribas, J., Bellet, M., Serra, V., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/772673 · Cited by 2
Cytotoxic lymphocytes use mechanosurveillance to target biophysical vulnerabilities in cancerPreprint
Tello‐Lafoz, M., Srpan, K., Hu, J. Y., Romin, Y., Calò, A., Hsu, K. C., Massagué, J., Huse, M., & Er, E. E. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.21.054304 · Cited by 2
Gautron, A., Bachelot, L., Quéméner, A. M., Corre, S., Aubry, M., Rambow, F., Paris, A., Tardif, N., Leclair, H. M., Coulouarn, C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.08.193102 · Cited by 2
Computational correction of off-targeting for CRISPR-Cas9 essentiality screensPreprint
Perez, A. R., Sala, L., Perez, R. K., & Vidigal, J. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/809970 · Cited by 2
Kim, E., Novak, L. C., Gheorghe, V., Bristow, C. A., & Hart, T. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.25.450004 · Cited by 2
OncoEnrichR: cancer-dedicated gene set interpretationPreprint
Nakken, S., Gundersen, S., Bernal, F. L. M., Polychronopoulos, D., Hovig, E. J., & Wesche, J. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2107.13247 · Cited by 2
Applications of CRISPRi and CRISPRa in Drug Discovery
Gilbert, L. A. (2022) · Wiley eBooks · doi:10.1002/9781119671404.ch10 · Cited by 2
Precision Discovery of Novel Inhibitors of Cancer Target HsMetAP1 from Vast Metagenomic DiversityPreprint
Liu, O. W., Akers, S., Alvarez, G., Brown, S., Cai, W., Charlop–Powers, Z., Crispell, K., Eyles, T. H., Ganesh, S., Goh, E.-B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.11.495772 · Cited by 2
Cancer-keeping genes as therapeutic targetsPreprint
Zhang, X., Pan, C., Wei, X., Yu, M., Liu, S., An, J., Yang, J., Wei, B., Hao, W., Yao, Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.13.495906 · Cited by 2
Computational Enhanced Hi-C data reveals the function of structural geometry in genomic regulationPreprint
He, Y., Xue, Y., Wang, J., Huang, Y., Liu, L., Huang, Y., & Gao, Y. Q. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.12.499232 · Cited by 2
Prioritizing Complex Disease Genes from Heterogeneous Public DatabasesPreprint
Gong, E., & Chen, J. Y. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.09.527562 · Cited by 2
Design of Peptide-Guided Protein Degraders with Structure-Agnostic Language ModelsPreprint
Brixi, G., Ye, T., Palepu, K., Hong, L., Yudistyra, V., Vincoff, S., Christopher, J., Li, X., Bhat, S., Monticello, C., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-1694183/v1 · Cited by 2
Genetic Functional Similarity Clustering Using CRISPR-Cas9 Knockout DataPreprint
Lee, J., Cho, M., Hong, H. S., No, K. T., & Cho, K. H. (2023) · Research Square · doi:10.21203/rs.3.rs-3013259/v1 · Cited by 2
Maia-Silva, D., Schier, A. C., Skopelitis, D. S., Kechejian, V., Alpsoy, A., Liverpool, J., Taatjes, D. J., & Vakoc, C. R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.24.563848 · Cited by 2
Optimal methods for analyzing targeted pairwise knockout screensPreprint
Chou, J., Anvar, N. E., Elghaish, R. A., Chen, J., & Hart, T. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.19.608665 · Cited by 2
Anticipating on-target resistance to WRN inhibitors in microsatellite unstable cancersPreprint
Orcholski, M. E., Laterreur, N., Masud, W., Shenoy, S., Chapdelaine, V., Bowlan, J., Minju-OP, A., Cabré-Romans, J.-J., Sack, T., Fiore, C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.22.700152 · Cited by 3
CDK12/13 inhibitor, CTX-439, suppresses tumor growth and potentiates BCL-2 family blockadePreprint
Yamakawa, H., Khatab, R., Mizutani, A., Ebara, S., Hirayama, T., Tanaka, S., Tarumoto, Y., Sugiyama, M., Sugino, S., Takano, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.20.706902 · Cited by 3
Self-citationExpression-Based Diagnosis, Treatment Selection, and Drug Development for Breast Cancer
Ye, Q., Wang, J., Ducatman, B. S., Raese, R. A., Rogers, J., Wan, Y., Dong, C., Padden, L., Pugacheva, E. N., Qian, Y. R., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310561 · Cited by 1
Voutsadakis, I. A. (2023) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20404 · Cited by 2
Genetic engineering in oncology based on CRISPR-Cas9 technology
Polatova, D., Madaminov, А. Y., Савкин, А. В., & Ибрагимова, Д. А. (2024) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2024-23-4-152-161 · Cited by 1
Wang, R., Deng, J., Zhang, M., Wang, Z., Wu, S., Liu, S., & Qi, L. (2024) · Oncology Letters · doi:10.3892/ol.2024.14823 · Cited by 1
Spirin, P., Vedernikova, V., Volkava, T., Morozov, A. V., Kleymenova, A. A., Zemskaya, A. S., Shyrokova, L., Porozov, Y. B., Glumakova, K. A., Lebedev, T. D., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17040416 · Cited by 1
Iyer, R., Deshpande, A. J., Pedgaonkar, A., Bala, P. A., Kim, T., Brien, G. L., Finlay, D., Vuori, K., Soragni, A., Wetterstein, H. I., et al. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00526-w · Cited by 1
CRISPR-Edited Cell Lines: A New Era in Functional Oncology Research
Rana, A. J., Hussain, M. S., Hanbashi, A., Kamli, F., Khan, G., Qadri, M. M., Al-Qahtani, S. A., Khan, M. G., Burle, S. S., Jakhmola, V., et al. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128413220250728182852 · Cited by 1
Lin, H.-K., Dai, J., & Pusztai, L. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07817-0 · Cited by 2
Innovative molecular targets for combatting metastasis in adrenocortical carcinoma
Kong, J., Chen, X., Fan, X., Fang, S., Zhang, Q., Zhang, L., Liao, C., He, Q., Xie, W., Xing, Y., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1516467 · Cited by 1
Large-scale CRISPR-Cas9 screens to define regulators of immune checkpoints
Mu, M., Melms, J. C., Ho, P., & Izar, B. (2025) · Methods in cell biology · doi:10.1016/bs.mcb.2025.10.011 · Cited by 1
dos Santos, C. S., Magalhães, A. C., Pinto, R., Carrilho, C., Pereira, C., Miguel, F., Borges, P., Santos, L. L., & Pereira, L. (2025) · Genes · doi:10.3390/genes16121403 · Cited by 1
Developing New Immunotherapy Approaches for Colorectal Cancer
Kelly, G., Nowlan, B., Tria, S. M., Nikkhoo, A., Bond, C., & Whitehall, V. (2025) · Cancers · doi:10.3390/cancers17243929 · Cited by 1
Harnessing mismatch repair deficiency for therapeutic targeting in cancers
Yenidogan, I., Tabori, U. Y., & Das, A. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2608031 · Cited by 2
The Werner syndrome RECQ helicase as a therapeutic target: new insights
Sidorova, J. M., & Monnat, R. J. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2619753 · Cited by 1
Expression-driven genetic dependency reveals targets for precision oncology
Elmas, A., Layden, H. M., Ellis, J. D., Bartlett, L. N., Zhao, X., Kawabata‐Iwakawa, R., Wang, Z., Obinata, H., Hiebert, S. W., & Huang, K.-L. (2026) · GigaScience · doi:10.1093/gigascience/giag011 · Cited by 1
Xi, Y., Yan, X., Liu, J., Li, S., Zhang, X., Hou, Y., Chu, M., & Yang, M. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48040339 · Cited by 1
Metadata
- Authors
- Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., Ansari, R., Harper, S., Jackson, D. A., McRae, R., Pooley, R., Wilkinson, P., van der Meer, D., Dow, D., Buser-Doepner, C., Bertotti, A., Trusolino, L., Stronach, E. A., Saez-Rodriguez, J., Yusa, K., & Garnett, M. J.
- Affiliations
- Wellcome Sanger Institute (GB)
- European Bioinformatics Institute (GB)
- Candiolo Cancer Institute (IT)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- Kyoto University (JP)
- Corresponding author
- Yusa, Kosuke
- Garnett, Mathew J.
- ORCID
- Venue
- Nature
- Published
- 2019-04-10
- Volume
- 568
- Issue
- 7753
- Pages
- 511-516
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2936686072
- Cited by
- 1,338
- References
- 64
- Citations by year
- 2026: 129 · 2025: 168 · 2024: 200 · 2023: 158 · 2022: 200 · 2021: 227 · 2020: 179 · 2019: 74
- FWCI
- 56.69
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- Wellcome Trust (C44943/A22536, SU2C-AACR-DT1213, 102696, 206194)
- Cancer Research UK (A22536, SU2C-AACR-DT1213, 102696, C44943/A22536)
- Associazione Italiana per la Ricerca sul Cancro (5X 1000, 21091, 20697, 18532)
- Stand Up To Cancer (SU2C-AACRDT1213)
- H2020 European Research Council (724748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- cancer cell lines, synthetic lethality, microsatellite instability, cancer dependency, genomic biomarkers, anticancer drug development
- MeSH terms
- Werner Syndrome Helicase, Synthetic Lethal Mutations, Gene Editing, Animals, Female, Humans, Neoplasm Transplantation, Neoplasms, Organ Specificity, Biomarkers, Tumor, Werner Syndrome, Reproducibility of Results, Genome, Human, Cell Line, Tumor, Mice, Microsatellite Instability, Drug Discovery, Molecular Targeted Therapy, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
